Company News-宜明昂科英文

2026-01-14

Palverafusp Alfa (IMM2510) Receives NMPA Approval for Phase II/III Clinical Trial in Endometrial Cancer

This milestone marks IMM2510's formal expansion into gynecologic oncology—a field with significant unmet medical needs—following its development in lung cancer.

2026-01-12

mmuneOnco Biopharmaceuticals' Timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis

Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp

2026-01-09

ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™

Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t

2026-01-07

ImmuneOnco Announces IND Acceptance for IMM0306 (Amulirafusp Alfa) Monotherapy in Primary Membranous Nephropathy, Advancing Comprehensive Autoimmune Pipeline

This marks another important milestone in IMM0306's pipeline expansion in autoimmune nephrology, signaling the innovative drug's progression into broader glomerular disease indications.

2026-01-06

ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation

SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,